Journal article

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

Selma Ugurel, Joachim Roehmel, Paolo A Ascierto, Jurgen C Becker, Keith T Flaherty, Jean J Grob, Axel Hauschild, James Larkin, Elisabeth Livingstone, Georgina Long, Paul Lorigan, Grant A McArthur, Antoni Ribas, Caroline Robert, Lisa Zimmer, Dirk Schadendorf, Claus Garbe

European Journal of Cancer | ELSEVIER SCI LTD | Published : 2020


BACKGROUND: Recent therapeutic strategies, particularly MAP kinase pathway inhibitors (BRAF, MEK) and immune checkpoint blockers (CTLA-4, PD-1), have been put on the test for their differential impact on long-term survival of metastatic melanoma patients. Various agents, dose regimens and combinations have been tested against each other vigorously within these two therapy groups. However, results from prospective head-to-head comparative trials comparing both strategies against each other are still lacking. METHODS: We performed an exploratory analysis of survival data from selected clinical trials representative for these two treatment strategies in advanced metastatic melanoma. 84 Kaplan-M..

View full abstract

University of Melbourne Researchers